999 |
The NEW Anti-platelet Agents and Platelet Reactivity Testing: Recommendations for Prasugrel and Ticagrelor and Lessons from GRAVATAS |
Roxana Mehran |
May. 12. 11 |
998 |
SES Revisited: The ¡°Unexpected¡± Results and Clinical Implications from BASKET-PROVE, SORT-OUT IV, and ISAR-TEST 4 |
David E. Kandzari |
May. 12. 11 |
997 |
Complications after TAVI: VARC Definitions, Frequency, and Management Considerations |
Patrick W. Serruys |
May. 12. 11 |
996 |
TAVI Perspectives from the European Theatre: New Indications and Multiple Devices |
Eberhard Grube |
May. 12. 11 |
995 |
Life after PARTNER (Inoperable and ¡°High Risk¡± Cohorts): Will TAVI Therapy Change Guidelines for AS Patients? |
Martin Bert Leon |
May. 12. 11 |
994 |
Behind Closed Doors: Functions of a Data Safety Monitoring Board |
Roxana Mehran |
May. 04. 10 |
993 |
Importance of Endpoint Adjudication (Clinical Events Committees) and Core Laboratories |
Donald E. Cutlip |
May. 04. 10 |
992 |
Nuances of Clinical Trials: Trial Size, Power Analysis, Sub Groups |
David Joel Cohen |
May. 04. 10 |
991 |
Types of Clinical Trials in Cardiology: The Rationale for Trial Design |
Roxana Mehran |
May. 04. 10 |
990 |
From DES to Percutaneous Valves: What Interventional Doctors Need to Know about Regulatory Barriers and Solutions to Global Device Evaluation |
Mitchell W. Krucoff |
May. 04. 10 |